ReviewFrontiers in pharmacology2019
Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- GABAergic dysfunction in Parkinson's disease: insights from in vivo proton magnetic resonance spectroscopy.NPJ Parkinson's disease · 2026Article
- Review
- Activation of the zona incerta GABAergic circuit for the treatment of pain hypersensitivity in Parkinson's disease mice model.The journal of headache and pain · 2025Article
- Machine learning identifies lactate metabolism biomarkers and deciphers immune infiltration landscapes in Parkinson's disease.Scientific reports · 2025Article
- Curcumin treatment reduces motor impairments and protects against rotenone-induced neurodegeneration in a rat model of Parkinson disease.Metabolic brain disease · 2025Article
- Preclinical Parkinson's Disease Models for Non-Motor Symptoms: Research Recommendations from a Systematic Review.Life (Basel, Switzerland) · 2025Review
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Nature's Remedies: Exploring the Potential of Propolis to Alleviate Non-Motor Manifestations of Parkinson's Disease.Molecules (Basel, Switzerland) · 2025Review
- Morphological and functional decline of the SNc in a model of progressive parkinsonism.NPJ Parkinson's disease · 2025Article
- Distinct cortical morphometric inverse divergence changes in Parkinson's disease correlate with transcriptional expression patterns.NeuroImage. Clinical · 2025Article
- Alteration of hippocampal parvalbumin interneurons underlies memory impairment in rat model of Parkinson's disease.Frontiers in behavioral neuroscience · 2025Article
- Human Leukocyte Antigen Polymorphism and Blood Biomarker Profiles in Parkinson's Disease: A Pilot Study in a Latvian Cohort.Biomedicines · 2024Article
- Transcriptional expression patterns of the cortical morphometric similarity network in progressive supranuclear palsy.CNS neuroscience & therapeutics · 2024Article
- RNA sequencing of olfactory bulb in Parkinson's disease reveals gene alterations associated with olfactory dysfunction.Neurobiology of disease · 2024Article
- Bioinformatics-based identification of key candidate genes and signaling pathways in patients with Parkinson's disease and obstructive sleep apnea.Sleep & breathing = Schlaf & Atmung · 2024Article
- Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit.European journal of medical research · 2024Review
- Morphometric similarity differences in drug-naive Parkinson's disease correlate with transcriptomic signatures.CNS neuroscience & therapeutics · 2024Article
- Sleep disorders cause Parkinson's disease or the reverse is true: Good GABA good night.CNS neuroscience & therapeutics · 2024Review
- Linalool, a Fragrance Compound in Plants, Protects Dopaminergic Neurons and Improves Motor Function and Skeletal Muscle Strength in Experimental Models of Parkinson's Disease.International journal of molecular sciences · 2024Article
- A review of the neurotransmitter system associated with cognitive function of the cerebellum in Parkinson's disease.Neural regeneration research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-motor symptoms are common in Parkinson's disease (PD) and they represent a major source of disease burden. Several non-motor manifestations, such as rapid eye movement sleep behavior disorder, olfactory loss, gastrointestinal abnormalities, visual alterations, cognitive and mood disorders, are known to precede the onset of motor signs. Nonetheless, the mechanisms mediating these alterations are poorly understood and probably involve several neurotransmitter systems. The dysregulation of GABAergic system has received little attention in PD, although the spectrum of non-motor symptoms might be linked to this pathway. This Mini Review aims to provide up-to-date information about the involvement of the GABAergic system for explaining non-motor manifestations in early stages of PD. Therefore, special attention is paid to the clinical data derived from patients with isolated REM sleep behavior disorder or drug-naïve patients with PD, as they represent prodromal and early stages of the disease, respectively. This, in combination with animal studies, might help us to understand how the disturbance of the GABAergic system is related to non-motor manifestations of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.